The main purpose of this study is to test the effectiveness of bevacizumab in combination
with radiation therapy to see what effects (good or bad) they have on patients with soft
tissue sarcoma. Bevacizumab is an antibody designed specifically to slow or stop the growth
of cancerous tumors by decreasing the blood supply to the tumor. Bevacizumab is approved by
the FDA in combination with intravenous 5-fluorouracil-based chemotherapy as a treatment for
patients with cancer of the colon or rectum that has spread. However, the use of bevacizumab
in combination with radiation for sarcomas is still under investigation.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)